17a-Hydroxylase-deficiency with unimpaired aldosterone formation in a male~eonate.
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The effect of growth hormone (GH) on adrenal androgen secretion was assessed in 7 patients (5 males, 2 females) with GH deficiency but normal ACTH-cortisol function. Patients ranged in age from 9 3/12-14 8/12 years. Plasma concentrations of dehydroep!androsterone (OHEA), its sulfate (OHEA-S) and androstenedione (~A), as well as urinary 17-ketosteroids and free cortisol were determined before, during short-term (2U/dx3) and after long-term (6 months) treatment with GH. The baseline, pretreatment plasma levels of OHEA-S were appropriate for the indiv!duals' degree of skeletal maturation, whereas plasma OHEA and~A were undetectable «42ng/dl and< 27ng/dl, respectively) in 5/7 subjects. No significant change was noted in the plasma androgen values or in the urinary 17-ketosteroid and free cortisol concentrations during the shortterm administration of GH. Despite a significant increase in growth velocity after 6 months of GH therapy, the pre-and posttreatment plasma and urinary ster·oid concentrations were not statistically different. These results fail to substantiate a role for GH in the secretion or metabolism of adrenal androgens. Thus, the delayed adrenarche and subnormal plasma adrenal androgen levels sometimes seen in GH deficient patients are not due to the absence of GH per se. The effects of ACTH and growth hormone (GH) on adrenocortical hom one secretion were studied in a 13-year-old girl with GH and thyrotropin deficiency but normal ACTH function. Cortisol secretion was measured by the sum of the urinar~excretions of tetrahydrocortisolfTHF), allotetrahydrocortisol (ATHF), and tetrahydrocortisone(THE . Adrenal androgen secretion was measured by the sum of androsteronelA) and etiocholanolone(E). The patient took a constant dally dose of desiccated thyroid(l50mgl during 5 successive periods: 3~ay control, 3 days of 1M ACTH (0.5mg/kg daily), lZ-day post-ACTH control, 6 days of 1M human GH (J.5mg daily), and 3 days of ACTH + GH at the previous doses. Control excretion of THF + ATHF + THE was 6.Omg/g creatinine and of A+E was Z.9mg/g creatinine, these values confirm normal endogenous ACTH function. Taking these levels as 100, excretion of ccrtisol and androgen metabolites rose to 240 and 190 respectively during ACTH and decreased to 107 and 105 respectively during the last 3 days of the post·ACTH control period. During the GH period, they fell to 66 and 72 respectively. When ACTH was added to GH, they rose to 170 and 103 respectively. Thus GH given alone deprassed secretion of both cortisol and adrenal androgens; this could be due to depression of endogenous ACTB secretion or to interference with the effect of ACTH on the adrenal. The data from the combined GH-ACTH period are compatible with either mechanIsm. 65.0 20 150 Genital skin fibroblast T receptors were normal in vitro 23 mol mg) but surprisingly 5a-reductase activity was redu~0.4 pM/Ug DNA/hr), although KID for T (0.12 uM) and NADPH (170 uM) were normal. T therapy corrected the micropenis but not the 5a-reductase deficiency. Family study suggested reduced 170H activity in the father and reduced 5a-reductase activity in the mother. Although the data suggest this boy may be a double heterozygote, a more direct link between 170H-deficiency and target cell 5a-reductase cannot be excluded.
Androstenedione was low (62,76,29 ng Idl). 170H-progesterone was normal or high (1B2,212,5Bl ng/dl) and increased after HCG (314, 3Bl, 13B6 ng/dl) , most in 3 with the lowest T. DHA before and after HCG was low in 1 and 2 (170-119, 17B-160 ng/dl), but normal in 3 (530-405 ng/dl). In urine, pregnanetriolone was present (0.62,0.32, 2.2rng/24h) and the 17-ketosteroids were normal or low (5.B,4.1, 1.4 mg124h). It is concluded that the degree of the defect may vary from partial (1 and 2) to marked (3) and that it may concern both, the 64-andA 5-pathways (1 and 2), or theA4-pathway only (3). Supported by the Swiss National Science Foundation (Grant No. 3.959.0BO). Serial sampling for determination of 17-CH-progesterone by radioimmuno&8say using dried capillary blood spots were rerformed throughout the day in eight infants with congenital adrenal hyperplaeia due to 21-hydroxylase deficiency in order to check the value of a single random sample for identification of patients and in monitoring therapy. The samples were taken in different part of the country and sent into the laboratory by mail. Marked variation of dot-17-OHP values in a range of diagnostic high level was observed before starting therapy without any sign of di urnal rhythm. Repeated sampling for dot-17 -CHP during the first weeks of glucocorticoid treatment showed persistent fluctuation at pathological high levele. While receiving glucocorticoid therapy for some monthe 17-CHP concentrations were suppressed showing moder.ately elevated levels in the morning and low levels in the evening. The blood-spot 17-CHP method can be used both for early identification and follow-up of congenital adrenal hyperplasia cases. however. 17-CHP profils over 24h are needed for monitoring therapy.
